Quarterly ResultJul 28, 2026, 12:56 PM
GSK Q2 Sales £8.4B (+5%); Core OP +7%, EPS +9%; Accelerates R&D
AI Summary
GSK plc reported strong Q2 2026 core results, with total sales reaching £8.4 billion, a 5% increase at constant exchange rates (CER), driven by robust performance in Specialty Medicines and Vaccines. Core operating profit grew 7% CER to £2.8 billion, and Core EPS increased by 9% CER to 50.5p. The company announced plans to accelerate R&D, expecting over 20 phase III trial starts in 2026, and initiated a 3-year "Accelerate Growth" program targeting £1.9 billion in annual savings by 2029. GSK reaffirmed its full-year 2026 guidance and declared a Q2 dividend of 17p per share.
Key Highlights
- Q2 2026 total sales £8.4 billion, up 5% CER.
- Specialty Medicines sales £3.8 billion, up 14% CER.
- Vaccines sales £2.3 billion, up 8% CER.
- Core operating profit £2.8 billion, up 7% CER.
- Core EPS 50.5p, up 9% CER.
- Plans 20+ phase III trial starts in 2026, up from previous 10.
- Initiates 3-year "Accelerate Growth" program targeting £1.9 billion annual savings by 2029.
- Reaffirms 2026 guidance for turnover, Core OP, and Core EPS growth.
- Declares Q2 2026 dividend of 17p per share and completed £2 billion share buyback.
Price Impact
More from GSK